Exhibit   

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact: Pattie Kushner (media) - +1 336-436-8263

Media@labcorp.com

Scott Frommer (investors) - +1 336-436-5076 

Investor@labcorp.com

Company Information: www.labcorp.com

358 South Main Street

Burlington, NC 27215 

Telephone: (336) 584-5171

LABCORP IS SCHEDULED TO PRESENT AT THE

39TH ANNUAL RAYMOND JAMES INSTITUTIONAL INVESTORS CONFERENCE

Burlington, NC, February 23, 2018 -LabCorp® (NYSE: LH) today announced it will participate at the 39th Annual Raymond James Institutional Investors Conference. LabCorp’s presentation is scheduled for Tuesday, March 6, 2018 at 8:40 AM (ET). 

A live audio webcast of the presentation will be available via the Company website at www.labcorp.com and archived for replay. 

About LabCorp

LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of over $10 billion in 2017. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com.

Forward-Looking Statements 

This press release contains forward-looking statements including with respect to estimated 2018 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.